Formic Acid

Formic Acid

SCHEMBL4666154

COc1ccc(S(=O)(=O)Nc2ccc(Nc3cc(-c4ccc(OCC5CCN(C)CC5)c(C)c4)ncn3)cc2)cc1F.O=CO

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.43
KIT P10721 1/20 0.43
EGFR P00533 8/20 0.43
PIK3R1 P27986 1/20 0.40
PIK3CA P42336 1/20 0.40
CCNT1 O60563 1/20 0.40
CDK9 P50750 1/20 0.40
MAPT P10636 4/20 0.39
TP53 P04637 2/20 0.39
KDR P35968 3/20 0.39
PDE4D Q08499 1/20 0.39
FGFR1 P11362 1/20 0.38
FLT1 P17948 1/20 0.38
FLT4 P35916 1/20 0.38
RET P07949 1/20 0.38
KIF5B P33176 1/20 0.38
ALDH1A1 P00352 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formic Acid SCHEMBL4665746 0.95 LMNA (0.45) LMNAKITEGFRCCNT1CDK9
Formic Acid SCHEMBL4664274 0.94 EGFR (0.45) LMNAKITEGFRPIK3R1PIK3CA
Formic Acid SCHEMBL4663939 0.92 LMNA (0.46) LMNAKITEGFRKDR
Formic Acid SCHEMBL4666184 0.91 EGFR (0.42) KITEGFRPDE4D
Formic Acid SCHEMBL4665784 0.89 ABL1 (0.45) EGFRCCNT1CDK9
Formic Acid SCHEMBL4665883 0.88 LMNA (0.44) LMNAKITEGFRCCNT1CDK9
Formic Acid SCHEMBL4665708 0.88 PIK3R1 (0.39) EGFRPIK3R1PIK3CAKDRFLT1
Formic Acid SCHEMBL4667444 0.88 PIK3R1 (0.42) EGFRPIK3R1PIK3CAKDRRET
Formic Acid SCHEMBL4665792 0.88 PDE4D (0.48) EGFRCCNT1CDK9MAPTKDR
Formic Acid SCHEMBL4664422 0.87 PIK3CA (0.51) KITEGFRPIK3R1PIK3CATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors ALTANA PHARMA AG (DE) 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors MAP3K19, MAP3K6, MAP3K20 LMNA 4261/4885KIT 675/4885EGFR 279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.